【Pharma Stock Earnings】Hengrui Pharmaceuticals 1276 Profits Surge 22% to 7.7 Billion RMB

SocialAnxietyStaker · 2026-03-25T14:32:02+00:00

Hengrui Pharmaceuticals announced 2025 profits of 7.711 billion yuan, up 21.69% year-over-year. Revenue reached 31.629 billion yuan, with innovative drug sales of 16.342 billion yuan, growing 26.09%. The company increased R&D investment with a cumulative total of 8.724 billion yuan and expects 53 innovative products to be approved for market launch from 2026 to 2028, including a new category weight-loss drug.

SocialAnxietyStaker

2026-03-25 14:32:02

Abstract generation in progress

Leading Chinese pharmaceutical company Hengrui Medicine (01276) announced that its profit for 2025 is expected to reach 7.711 billion yuan (RMB), an increase of 21.69% year-on-year.

During the period, revenue was 31.629 billion yuan, up 13.02% year-on-year. Among them, sales of innovative drugs amounted to 16.342 billion yuan, a 26.09% increase year-on-year, accounting for 58.34% of total drug sales.

In terms of innovative drug sales, anti-tumor products generated 13.24 billion yuan, an 18.52% increase year-on-year, accounting for 81.02% of total innovative drug sales; non-tumor products earned 3.102 billion yuan, a 73.36% increase year-on-year, accounting for 18.98% of total innovative drug sales.

During the period, the company’s cumulative R&D investment was 8.724 billion yuan, accounting for 27.58% of operating income. Of this, 6.961 billion yuan was spent on expense-based R&D, a 5.74% increase year-on-year. Additionally, 7 Class 1 innovative drugs, 1 Class 2 innovative drug, and 6 newly approved innovative drugs for new indications have been approved for market. Currently, 24 Class 1 innovative drugs and 5 Class 2 new drugs have been approved in China, with over 100 proprietary innovative products in clinical development and more than 400 clinical trials underway domestically and internationally.

In terms of R&D pipeline, last year, 15 applications for market approval were accepted by the China National Medical Products Administration (NMPA), 28 products advanced to Phase III clinical trials, 61 to Phase II, and 28 innovative products entered Phase I clinical trials for the first time.

The company forecasts that between 2026 and 2028, approximately 53 innovative products are expected to be approved for market launch, including the new weight-loss drug “GLP-1/GIP dual receptor agonist HRS9531.” For new indications, Roche’s trastuzumab (Herceptin) is expected to be approved for colorectal cancer, breast cancer, and other conditions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.